SCHEMBL1491464

SCHEMBL1491464

Nc1cccc(OCCBr)c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.61
CYP3A4 P08684 3/20 0.60
TP53 P04637 1/20 0.60
MAOB P27338 2/20 0.55
ALDH1A1 P00352 1/20 0.50
APP P05067 1/20 0.50
LTA4H P09960 1/20 0.45
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
HSP90AA1 P07900 1/20 0.43
CASP1 P29466 1/20 0.42
RECQL P46063 1/20 0.42
PRSS1 P07477 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8254027 0.90 TSHR (0.64) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL29502076 0.87 CYP3A4 (0.69) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL3791936 0.87 CYP3A4 (0.69) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL29437038 0.85 TSHR (0.72) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL6756802 0.85 TSHR (0.72) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL441825 0.85 TSHR (0.79) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL29437009 0.85 TSHR (0.79) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL8155382 0.85 SMN1; SMN2 (0.50) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL18045584 0.83 TSHR (0.82) TSHRCYP3A4TP53MAOBALDH1A1
SCHEMBL18045563 0.83 TSHR (0.82) TSHRCYP3A4TP53MAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105073741-B Phthalazinones and isoquinolinones as ROCK inhibitors 百时美施贵宝公司 2017-08-08 CN disclosed
CN-103189373-B The Triazolopyridine replaced BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-04-06 CN disclosed
US-9133104-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2015-09-15 US disclosed
US-20140163042-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-12 US disclosed
US-20140163042-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-12 US disclosed
US-20140163042-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-12 US disclosed
CN-103189373-A Substituted triazolopyridines BAYER IP GMBH 2013-07-03 CN disclosed
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 US disclosed
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 US disclosed
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 US disclosed
US-7939666-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-05-10 US disclosed
US-7939666-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-05-10 US disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 EP disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 EP disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed
EP-1879895-A1 ENZYME INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-23 EP disclosed
WO-2006117549-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed
WO-2006117549-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116318-A1 Enzyme Inhibitors HDAC1, HDAC11, HDAC7 TSHR 3751/4885CYP3A4 1852/4885TP53 342/4885
US-20140163042-A1 ENZYME INHIBITORS HAT1, NR2E1, HDAC3 TSHR 894/4885CYP3A4 522/4885TP53 1898/4885
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 TSHR 1357/4885CYP3A4 902/4885TP53 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.